Q4 2024 · 13F-HR
GILEAD SCIENCES, INC. (GILD)holdings as filed
Filed 2025-02-13 · accession 0001123292-25-000079
$1.55B
Reported value
16
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03940C100 | ACLXGBX | ARCELLX INC | $515.4M | 33.2% | 6,720,803 | Common | SOLE |
| 36315X101 | LKFT | GALAPAGOS NV | $461.7M | 29.8% | 16,707,477 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $447.6M | 28.9% | 30,061,124 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $34.9M | 2.25% | 2,209,471 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $19.0M | 1.23% | 452,527 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $15.4M | 0.99% | 4,126,119 | Common | SOLE |
| 52187K200 | CYPH | LEAP THERAPEUTICS INC | $15.3M | 0.99% | 5,319,148 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $15.0M | 0.97% | 4,854,443 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $8.7M | 0.56% | 9,105,451 | Common | SOLE |
| 019818103 | — | ALLOVIR INC | $7.0M | 0.45% | 16,635,286 | Common | SOLE |
| 43906K209 | HOOK | HOOKIPA PHARMA INC | $3.8M | 0.24% | 1,875,945 | Common | SOLE |
| 45175G108 | — | IKENA ONCOLOGY INC | $3.3M | 0.21% | 2,008,338 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $2.5M | 0.16% | 1,156,689 | Common | SOLE |
| 91864C107 | BRNS | BARINTHUS BIOTHERAPEUTICS PL | $749,384 | 0.05% | 620,351 | Common | SOLE |
| 00847G804 | AGEN | AGENUS INC | $634,757 | 0.04% | 231,663 | Common | SOLE |
| 50107A104 | KRON1USD | KRONOS BIO INC | $179,139 | 0.01% | 188,567 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.